
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals Inc. is poised for significant revenue growth, with projected Khindivi-related revenues estimated to increase from $3 million in 2025 to a peak of $28 million by 2030. The company's management has demonstrated strong commercial execution, leading to a raised probability of launch for Khindivi to 100% and an anticipated launch date moved up to June. Additionally, the potential for increased market penetration, projected to rise from 40% to 60%, underscores the company's capability to meet unmet patient needs and reinforces a positive outlook for future financial performance.
Bears say
The financial analysis indicates a cautious outlook on Eton Pharmaceuticals due to the reliance on a high discount rate of 11%, which typically suggests increased risk and uncertainty regarding future cash flows. Additionally, the low terminal growth rate of 2% raises concerns about the company's long-term revenue potential, limiting growth expectations beyond the near term. These factors contribute to a relatively modest adjustment in the company's price target, reflecting underlying skepticism about Eton Pharmaceuticals's ability to significantly enhance shareholder value in the near future.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares